Upregulation of long non-coding RNA FOXP4-AS1 and its regulatory network in hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun. 2017;1(7):595–608. doi:10.1002/hep4.104729404481
   PubMed Web of Science ®Google Scholar
• Hu X, Jiang J, Xu Q, Ni C, Yang L, Huang D. A systematic review of long noncoding RNAs in hepatocellular carcinoma: molecular mechanism and clinical implications. Biomed Res Int. 2018;2018:8126208. doi:10.1155/2018/812620830105249
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–1261. doi:10.1038/nm.398126540387
   PubMed Web of Science ®Google Scholar
• Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45(8):1895–1910. doi:10.1016/j.biocel.2013.05.03023748105
   PubMed Web of Science ®Google Scholar
• Liao X, Yang C, Huang R, et al. Identification of potential prognostic long non-coding RNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cell Physiol Biochem. 2018;48(5):1854–1869. doi:10.1159/00049250730092592
   PubMedGoogle Scholar
• Li J, Lian Y, Yan C, et al. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Cell Prolif. 2017;50(1). doi:10.1111/cpr.12368.
   Web of Science ®Google Scholar
• Yang L, Ge D, Chen X, et al. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2. Biochem Biophys Res Commun. 2018;502(4):493–500. doi:10.1016/j.bbrc.2018.05.19829859193
   PubMed Web of Science ®Google Scholar
• Jia RR, Zhong JH, Huo RR, et al. Correlation between serum prealbumin and prognosis of patients with hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2019;119(6):794–800. doi:10.1002/jso.2537830648280
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–260. doi:10.1159/00048803530319983
   PubMed Web of Science ®Google Scholar
• Yoon EL, Yeon JE, Ko E, et al. An explorative analysis for the role of serum miR-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma. J Korean Med Sci. 2017;32(2):212–220. doi:10.3346/jkms.2017.32.2.21228049231
   PubMed Web of Science ®Google Scholar
• Jiang C, Long J, Liu B, et al. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2017;36(1):99. doi:10.1186/s13046-017-0568-328750679
   PubMedGoogle Scholar
• Lv L, Wang X, Ma T. microRNA-944 inhibits the malignancy of hepatocellular carcinoma by directly targeting IGF-1R and deactivating the PI3K/Akt signaling pathway. Cancer Manag Res. 2019;11:2531–2543. doi:10.2147/CMAR.S19981831114322
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu W, Meng W, et al. Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-beta/Smad signaling in hepatocellular carcinoma. Onco Targets Ther. 2018;11:1929–1939. doi:10.2147/OTT.S15441629670368
   PubMed Web of Science ®Google Scholar
• Ding H, Ye ZH, Wen DY, et al. Downregulation of miR1365p in hepatocellular carcinoma and its clinicopathological significance. Mol Med Rep. 2017;16(4):5393–5405. doi:10.3892/mmr.2017.727528849100
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Liang B, Jiang K, Zhang HY. Down-regulation of miR-655-3p predicts worse clinical outcome in patients suffering from hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2017;21(4):748–752.28272708
   PubMed Web of Science ®Google Scholar
• Liu S, Yang TB, Nan YL, et al. Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma. Cancer Med. 2017;6(7):1512–1522. doi:10.1002/cam4.106728639733
   PubMed Web of Science ®Google Scholar
• Fu X, Wen H, Jing L, et al. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108(4):620–631. doi:10.1111/cas.1317728132399
   PubMed Web of Science ®Google Scholar
• Chen J, Rajasekaran M, Xia H, et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway. Gut. 2016;65(9):1522–1534. doi:10.1136/gutjnl-2015-31062526941395
   PubMed Web of Science ®Google Scholar
• Tian Y, Wu J, Chagas C, et al. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC). BMC Cancer. 2018;18(1):1187. doi:10.1186/s12885-018-4242-830497429
   PubMedGoogle Scholar
• Chen T, Huang H, Zhou Y, et al. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3beta signaling pathways. J Exp Clin Cancer Res. 2018;37(1):193. doi:10.1186/s13046-018-0866-430111352
   PubMedGoogle Scholar
• Hayashi T, Ohtsuka M, Okamura D, et al. Cytoskeleton-associated protein 2 is a potential predictive marker for risk of early and extensive recurrence of hepatocellular carcinoma after operative resection. Surgery. 2014;155(1):114–123. doi:10.1016/j.surg.2013.06.00924238125
   PubMed Web of Science ®Google Scholar
• Regel I, Eichenmuller M, Joppien S, et al. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer. 2012;11:9. doi:10.1186/1476-4598-11-922401581
   PubMed Web of Science ®Google Scholar